Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 6/20 | 0.47 |
| ▸ | MAOB | P27338 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | TLR4 | O00206 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14102978 | 0.87 | NPC1 (0.61) | NPC1RAB9ATDP1APPMAOB | |
| SCHEMBL16093963 | 0.82 | CYP1A2 (0.47) | NPC1RAB9ATDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL25307498 | 0.79 | MAOB (0.50) | NPC1RAB9ATDP1APPMAOB | |
| SCHEMBL31662278 | 0.77 | APP (0.51) | NPC1RAB9ATDP1APPMAOB | |
| SCHEMBL1554192 | 0.77 | MAOB (0.54) | NPC1RAB9ATDP1APPMAOB | |
| SCHEMBL25798559 | 0.77 | HDAC8 (0.50) | NPC1RAB9ATDP1APPMAOB | |
| SCHEMBL29557093 | 0.76 | HDAC8 (0.42) | NPC1RAB9AAPPMAOBSMN1; SMN2 | |
| SCHEMBL1250536 | 0.75 | NPC1 (0.57) | NPC1RAB9ATDP1APPMAOB | |
| SCHEMBL21244006 | 0.74 | APP (0.61) | NPC1RAB9ATDP1APPMAOB | |
| SCHEMBL15716155 | 0.74 | ALDH1A1 (0.39) | NPC1SMN1; SMN2ALDH1A1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3529247-B1 | HETEROCYCLIC FXR MODULATORS | HEPAGENE THERAPEUTICS HK LTD (HK) | 2021-08-18 | — | — | EP | disclosed |
| EP-3529247-B1 | HETEROCYCLIC FXR MODULATORS | HEPAGENE THERAPEUTICS HK LTD (HK) | 2021-08-18 | — | — | EP | disclosed |
| US-10899723-B2 | Heterocyclic containing cyclopropyl FXR modulators | Hepagene Therapeutics (HK) Limited (HK) | 2021-01-26 | — | — | US | disclosed |
| US-20190248752-A1 | HETEROCYCLIC FXR MODULATORS | Hepagene Therapeutics (HK) Limited (HK) | 2019-08-15 | — | — | US | disclosed |
| WO-2018075207-A1 | HETEROCYCLIC FXR MODULATORS | HEPAGENE THERAPEUTICS, INC. (VG) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899723-B2 | Heterocyclic containing cyclopropyl FXR modulators | NR1H4, FXR1, GPBAR1 | NPC1 87/4885RAB9A 1421/4885TDP1 4740/4885 |
| US-20190248752-A1 | HETEROCYCLIC FXR MODULATORS | NR1H4, FXR1, NR1H2 | NPC1 157/4885RAB9A 1852/4885TDP1 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.